Relay Therapeutics Inc (NASDAQ:RLAY) shares, rose in value on Wednesday, February 12, with the stock price up by 0.53% to the previous day’s close as strong demand from buyers drove the stock to $3.76.
Actively observing the price movement in the last trading, the stock closed the session at $3.74, falling within a range of $3.61 and $3.76. The value of beta (5-year monthly) was 1.675. Referring to stock’s 52-week performance, its high was $11.16, and the low was $3.50. On the whole, RLAY has fluctuated by -21.34% over the past month.
With the market capitalization of Relay Therapeutics Inc currently standing at about $629.36 million, investors are eagerly awaiting this quarter’s results, scheduled for in March.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 6.08M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RLAY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RLAY currently trading nearly -15.38% and -15.87% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.60, while the 7-day volatility ratio is showing 6.90% which for the 30-day chart, stands at 9.35%. Furthermore, Relay Therapeutics Inc (RLAY)’s beta value is 1.62, and its average true range (ATR) is 0.36.
A comparison of Relay Therapeutics Inc (RLAY) with its peers suggests the former has fared considerably weaker in the market. RLAY showed an intraday change of 0.53% in last session, and over the past year, it shrunk by -58.64%%.
Data on historical trading for Relay Therapeutics Inc (NASDAQ:RLAY) indicates that the trading volumes over the past 10 days have averaged 1.19 and over the past 3 months, they’ve averaged 2.37 million. According to company’s latest data on outstanding shares, there are 166.89 million shares outstanding.
Nearly 26.35% of Relay Therapeutics Inc’s shares belong to company insiders and institutional investors own 76.33% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.66 million shares as on 2025-01-31, resulting in a short ratio of 5.62. According to the data, the short interest in Relay Therapeutics Inc (RLAY) stood at 1135.00 of shares outstanding as of 2025-01-31; the number of short shares registered in 2024-12-31 reached 14.95 million. The stock has fallen by -8.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RLAY stock heading into the next quarter.
